AGEN

Agenus Inc. (AGEN) | Rumor.io

Agenus

AGEN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,168

Bullish sentiment (50-day avg)81%

Price to earnings ratio3.02

Market capitalization425.9M

Earnings per share2.99

Dividend yield (TTM)—

Revenue (annual)114.2M

Net income (annual)-3.1M

Social

What share of all stock conversation is about AGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0% +0	0% +0	0% 0

Sep 29

Agenus Inc. (AGEN) has broken out to a 52-week high, according to a social media post.
The company's investigational combination product, BOT+BAL, is expected to see its core composition-of-matter and underlying technology patents expire in the late 2030s.
Agenus Inc. (AGEN) reported revenue of $114.2M in 2025, a 10.4% year-over-year increase.

Generated by AI

Sentiment

Of the messages about AGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	54.55% -34.16	82.11% -2.64	82.21% +8.43	62.87% +5.38
Bearish	45.45% +34.16	17.89% +2.64	17.79% -8.43	37.13% -5.38

Bullish· Sep 28

The AI model suggests that Agenus Inc. is close to a breakout to $12, with technical indicators showing a lack of immediate resistance, creating a psychological runway toward double digits.
Agenus Inc. is expected to reach $100 by the end of next year, with the team's execution and the drug's positive results being key factors in the stock's success.
Agenus Inc. has been initiated with a buy rating and a price target of $19.00 by Rodman & Renshaw, and the stock's upward move is justified by the recent CRC data, with a positive readout of data for ovarian cancer potentially moving the stock into an extremely bullish mode.

Bearish· Jul 15

The Agenus Inc. (AGEN) trial enrollment and support have been terminated, which could negatively impact the company's progress.
The stock price of Agenus Inc. (AGEN) has experienced a significant drop, with some short sellers already taking profits.
Agenus Inc. (AGEN) is seen as a failing team by the market, with the CEO's performance being particularly criticized, and the company's overall prospects looking bleak.

Generated by AI

Topics

Of the messages about AGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	35.48%	34.29%	17.02%
Technical Analysis	0%	38.71%	17.14%	3.39%
Analysts	0%	25.81%	48.57%	38.97%
Macro	0%	0%	0%	37.4%
Earnings	0%	0%	0%	1.97%
Controversies	0%	0%	0%	1.24%

Earnings· Mar 14

Agenus Inc. ($AGEN) reported a loss of $0.40 EPS, missing the consensus estimate by $0.12.
The company's FQ4 revenue came in at $6.45M, also missing the Estimize revenue consensus by $0.11M.
Agenus Inc.'s CEO, Garo Armen, discussed the company's Q4 2018 results on an earnings call, providing further insight into the company's performance.

Announcements· Jul 13

Agenus Inc. (AGEN) announced an oversubscribed private placement of up to $340M to advance its registrational Phase 3 trial, ROBBIN, for neoadjuvant treatment of microsatellite-stable (MSS) colon cancer.
The financing includes $85M upfront and up to $255M upon warrant exercise, with the proceeds primarily funding the ROBBIN trial, an 850-patient study evaluating botensilimab plus balstilimab (BOT+BAL) in MSS colon cancer.
Agenus will discontinue financial support for its ongoing BATTMAN Phase 3 study in late-line metastatic MSS CRC and will honor its obligations to patients currently receiving treatment.

Technical Analysis· Jul 13

The weekly chart for $AGEN is showing a breakout, with potential for a move to $10.00.
Agenus has held above the Volume-Weighted Average Price (VWAP) for most of the day, indicating steady buying pressure and solid intraday strength.
The company's oncology pipeline and immunotherapy assets may be underestimating the market, and a strong close could be a good sign for the stock, with potential for a move to $10+ and beyond.

Generated by AI

Community

Of the messages about AGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	86%	89%	61.12%	56.47%
Newcomers	14%	11%	38.88%	43.53%

Regulars· Sep 28

Agenus Inc. ($AGEN) is expected to break out to $12 following a clean breakout above $8.76-$8.85, with technical indicators showing a lack of immediate structural resistance.
A buyout could be a welcome catalyst for the stock, and the company is underpriced; an initiation of coverage by Rodman & Renshaw with a buy rating and price target of $19 supports this view.
A positive readout of data for ovarian cancer on October 3 could move the stock into a bullish mode, and the company's market cap is close to reaching half a billion dollars, with no reason why it shouldn't reach $1 billion.

Newcomers· Jul 13

Newcomers are focused on the recent surge in Agenus Inc.'s stock price, with some users questioning the company's valuation and others speculating about the potential for further growth.
The influx of new capital from a private placement deal is being closely watched, with some users optimistic about the company's prospects and others expressing caution due to the stock's low float and volatility.
Several users are highlighting the potential for Agenus Inc. to advance its Phase 3 trial in colon cancer, which could be a major catalyst for the stock's growth.

Generated by AI

News

Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock Soaring - Caution Advised

Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN stock here.

19h agoSeeking Alpha

Agenus: Hot Times As It Trudges Towards BOT/BAL Submission (NASDAQ:AGEN)

22h agoSeeking Alpha

Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing

10d agoYahoo Finance

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

LEXINGTON, Mass., September 10, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

20d agoYahoo Finance

Agenus to Participate in Upcoming September Investor Conferences

LEXINGTON, Mass., August 31, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September.

1mo agoYahoo Finance

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

LEXINGTON, Mass., August 28, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.

1mo agoYahoo Finance Singapore

Also Discussed

Investors talking about AGEN also mention

#	Name	Attention
1	MiNK Therapeutics, Inc.INKT	0%new
2	Incyte Corp.INCY	0%new
3	Exelixis Inc.EXEL	0%-0.03
4	Edap Tms S.A.EDAP	0%0
5	BLCM - Bellicum Pharmaceuticals, Inc.	——
6	AFMD - Affimed N.V.	——
7	Celldex Therapeutics IncCLDX	0%0
8	Cerus CorporationCERS	0%new
9	Cytokinetics, IncorporatedCYTK	0.01%+0
10	FOLD - Amicus Therapeutics, Inc.	——

Agenus Inc.

Healthcare
Biotechnology

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors. Its current portfolio also includes vaccine adjuvants and cell therapy programs, supported by proprietary discovery platforms and in-house manufacturing and clinical development capabilities. The company’s lead programs center on botensilimab and balstilimab, which are being advanced in multiple solid-tumor settings, including colorectal cancer and other difficult-to-treat cancers. Agenus also works through subsidiaries and partners to support adoptive cell therapies and adjuvant technologies, giving it a broad role across the immunotherapy value chain. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. remains a specialist developer in the cancer immunotherapy market.

Website

Location

3 Forbes Road

Lexington, MA, 02421-7305

United States

Social

What share of all stock conversation is about AGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0% +0	0% +0	0% 0

Sep 29

Agenus Inc. (AGEN) has broken out to a 52-week high, according to a social media post.
The company's investigational combination product, BOT+BAL, is expected to see its core composition-of-matter and underlying technology patents expire in the late 2030s.
Agenus Inc. (AGEN) reported revenue of $114.2M in 2025, a 10.4% year-over-year increase.

Generated by AI

Sentiment

Of the messages about AGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	54.55% -34.16	82.11% -2.64	82.21% +8.43	62.87% +5.38
Bearish	45.45% +34.16	17.89% +2.64	17.79% -8.43	37.13% -5.38

Bullish· Sep 28

The AI model suggests that Agenus Inc. is close to a breakout to $12, with technical indicators showing a lack of immediate resistance, creating a psychological runway toward double digits.
Agenus Inc. is expected to reach $100 by the end of next year, with the team's execution and the drug's positive results being key factors in the stock's success.
Agenus Inc. has been initiated with a buy rating and a price target of $19.00 by Rodman & Renshaw, and the stock's upward move is justified by the recent CRC data, with a positive readout of data for ovarian cancer potentially moving the stock into an extremely bullish mode.

Bearish· Jul 15

The Agenus Inc. (AGEN) trial enrollment and support have been terminated, which could negatively impact the company's progress.
The stock price of Agenus Inc. (AGEN) has experienced a significant drop, with some short sellers already taking profits.
Agenus Inc. (AGEN) is seen as a failing team by the market, with the CEO's performance being particularly criticized, and the company's overall prospects looking bleak.

Generated by AI

Topics

Of the messages about AGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	35.48%	34.29%	17.02%
Technical Analysis	0%	38.71%	17.14%	3.39%
Analysts	0%	25.81%	48.57%	38.97%
Macro	0%	0%	0%	37.4%
Earnings	0%	0%	0%	1.97%
Controversies	0%	0%	0%	1.24%

Earnings· Mar 14

Agenus Inc. ($AGEN) reported a loss of $0.40 EPS, missing the consensus estimate by $0.12.
The company's FQ4 revenue came in at $6.45M, also missing the Estimize revenue consensus by $0.11M.
Agenus Inc.'s CEO, Garo Armen, discussed the company's Q4 2018 results on an earnings call, providing further insight into the company's performance.

Announcements· Jul 13

Agenus Inc. (AGEN) announced an oversubscribed private placement of up to $340M to advance its registrational Phase 3 trial, ROBBIN, for neoadjuvant treatment of microsatellite-stable (MSS) colon cancer.
The financing includes $85M upfront and up to $255M upon warrant exercise, with the proceeds primarily funding the ROBBIN trial, an 850-patient study evaluating botensilimab plus balstilimab (BOT+BAL) in MSS colon cancer.
Agenus will discontinue financial support for its ongoing BATTMAN Phase 3 study in late-line metastatic MSS CRC and will honor its obligations to patients currently receiving treatment.

Technical Analysis· Jul 13

The weekly chart for $AGEN is showing a breakout, with potential for a move to $10.00.
Agenus has held above the Volume-Weighted Average Price (VWAP) for most of the day, indicating steady buying pressure and solid intraday strength.
The company's oncology pipeline and immunotherapy assets may be underestimating the market, and a strong close could be a good sign for the stock, with potential for a move to $10+ and beyond.

Generated by AI

Community

Of the messages about AGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	86%	89%	61.12%	56.47%
Newcomers	14%	11%	38.88%	43.53%

Regulars· Sep 28

Agenus Inc. ($AGEN) is expected to break out to $12 following a clean breakout above $8.76-$8.85, with technical indicators showing a lack of immediate structural resistance.
A buyout could be a welcome catalyst for the stock, and the company is underpriced; an initiation of coverage by Rodman & Renshaw with a buy rating and price target of $19 supports this view.
A positive readout of data for ovarian cancer on October 3 could move the stock into a bullish mode, and the company's market cap is close to reaching half a billion dollars, with no reason why it shouldn't reach $1 billion.

Newcomers· Jul 13

Newcomers are focused on the recent surge in Agenus Inc.'s stock price, with some users questioning the company's valuation and others speculating about the potential for further growth.
The influx of new capital from a private placement deal is being closely watched, with some users optimistic about the company's prospects and others expressing caution due to the stock's low float and volatility.
Several users are highlighting the potential for Agenus Inc. to advance its Phase 3 trial in colon cancer, which could be a major catalyst for the stock's growth.

Generated by AI

Agenus

Social

Sep 29

Bullish· Sep 28

Bearish· Jul 15

Earnings· Mar 14

Announcements· Jul 13

Technical Analysis· Jul 13

Regulars· Sep 28

Newcomers· Jul 13

Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock Soaring - Caution Advised

Agenus: Hot Times As It Trudges Towards BOT/BAL Submission (NASDAQ:AGEN)

Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus to Participate in Upcoming September Investor Conferences

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Also Discussed

Agenus Inc.

Company Information

Location

Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock Soaring - Caution Advised

Agenus: Hot Times As It Trudges Towards BOT/BAL Submission (NASDAQ:AGEN)

Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus to Participate in Upcoming September Investor Conferences

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Also Discussed

Social

Sep 29

Bullish· Sep 28

Bearish· Jul 15

Earnings· Mar 14

Announcements· Jul 13

Technical Analysis· Jul 13

Regulars· Sep 28

Newcomers· Jul 13